Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54781532 dose-response study in moderately to severely active ulcerative colitis
NL-OMON40180Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peficitinib in autoimmune colitis (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in Mayo score at Week 8. Started Mar 2014; status: active, not recruiting.
02
Drugs
peficitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40180.